Accessibility Menu
CytomX Therapeutics logo

CytomX Therapeutics

(NASDAQ) CTMX

Current Price$3.39
Market Cap$711.89M
Since IPO (2015)-74%
5 Year-47%
1 Year+47%
1 Month-11%

CytomX Therapeutics Financials at a Glance

Market Cap

$711.89M

Revenue (TTM)

$35.54M

Net Income (TTM)

-$59.14M

EPS (TTM)

-$0.36

P/E Ratio

-8.99

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$3.39

Volume

28,894,577.237

Open

$3.27

Previous Close

$3.40

Daily Range

$3.23 - $3.48

52-Week Range

$1.72 - $8.21

Estimated Earnings Date

Aug 6, 2026

CTMX: Motley Fool Moneyball Superscore

63

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CytomX Therapeutics

Industry

Biotechnology

Employees

69

CEO

Sean A. McCarthy, PhD, MBA

Headquarters

South San Francisco, CA 94080, US

CTMX Financials

Key Financial Metrics (TTM)

Gross Margin

99.29%

Operating Margin

-181.92%

Net Income Margin

-166.40%

Return on Equity

-36.61%

Return on Capital

-21.66%

Return on Assets

-16.46%

Earnings Yield

-11.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$711.89M

Shares Outstanding

217.70M

Volume

28.89M

Avg. Volume

4.07M

Financials (TTM)

Gross Profit

$35.29M

Operating Income

-$64.66M

EBITDA

-$57.67M

Operating Cash Flow

-$80.09M

Capital Expenditure

-$101.00K

Free Cash Flow

-$80.19M

Cash & ST Invst.

$346.71M

Total Debt

$2.86M

CytomX Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$10.26M

-79.9%

Gross Profit

$10.01M

-80.3%

Gross Margin

97.55%

N/A

Market Cap

$711.89M

N/A

Market Cap/Employee

$5.98M

N/A

Employees

119

N/A

Net Income

-$18.25M

-177.6%

EBITDA

-$17.94M

-174.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$346.71M

+334.0%

Total Debt

$2.86M

-65.0%

Accounts Receivable

$646.00K

-67.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$2.86M

-46.0%

Return on Assets

-16.46%

N/A

Return on Invested Capital

-19.87%

N/A

Free Cash Flow

-$25.55M

-20.7%

Operating Cash Flow

-$25.55M

-21.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNAGinkgo Bioworks Holdings, Inc.
$10.25+7.11%
REPLReplimune Group, Inc.
$11.63+4.49%
MGTXMeiraGTx Holdings plc
$12.11+5.03%
AVXLAnavex Life Sciences Corp.
$2.62+6.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.87+0.02%
SPCXSpace Exploration Technologies
$153.23+0.00%
ONDSOndas
$7.83+0.02%
KEELKeel Infrastructure
$6.03+0.03%

Questions About CTMX

What is the current price of CytomX Therapeutics?

CytomX Therapeutics is trading at $3.40 per share.

What is the 52-week range for CytomX Therapeutics?

Over the past 52 weeks, CytomX Therapeutics has traded between $1.72 and $8.21.

How much debt does CytomX Therapeutics have?

As of the most recent reporting period, CytomX Therapeutics reported total debt of $2.86M.

How much cash does CytomX Therapeutics have on hand?

CytomX Therapeutics reported $28.83M in cash and cash equivalents in its most recent financial results.

What is CytomX Therapeutics’s dividend yield?

CytomX Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.